Case Control Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Oct 7, 2018; 24(37): 4272-4280
Published online Oct 7, 2018. doi: 10.3748/wjg.v24.i37.4272
Table 1 Comparison of clinical data in the two groups
Hepatic fibrosis group (n = 245)Control group (n = 93)t2 valueP value
Sex (male/%)136/55.5145/48.391.3750.241
Age40.31 ± 10.4737.82 ± 13.721.7850.075
SWV (m/s)3.02 ± 0.801.52 ± 0.6216.3100.000
ALT (U/L)52.23 ± 26.0246.87 ± 87.451.4870.138
AST (U/L)41.12 ± 12.7236.14 ± 14.521.6070.109
AST/ALT0.93 ± 0.410.74 ± 0.234.2210.000
PLT (109/L)184.02 ± 02.21192.37 ± 37.421.2200.223
TBIL (μmol/L)19.83 ± 9.8318.75 ± 8.721.5700.117
HA (μg/L)113.24 ± 24.7863.23 ± 23.5415.7480.000
LN (μg/L)36.21 ± 21.3434.21 ± 10.281.4850.139
CIV (μg/L)33.28 ± 28.2020.89 ± 9.564.1440.000
PIIINP (μg/L)36.29 ± 29.4532.87 ± 2.321.1000.272
APRI0.85 ± 0.610.62 ± 0.523.2190.001
FIB-41.63 ± 0.891.17 ± 0.624.5780.000